Robert J Israel Net Worth

The estimated Net Worth of Robert J Israel is at least 440 千$ dollars as of 11 June 2015. Robert Israel owns over 2,000 units of Progenics Pharmaceuticals stock worth over 151,905$ and over the last 21 years Robert sold PGNX stock worth over 288,582$.

Robert Israel PGNX stock SEC Form 4 insiders trading

Robert has made over 90 trades of the Progenics Pharmaceuticals stock since 2004, according to the Form 4 filled with the SEC. Most recently Robert exercised 2,000 units of PGNX stock worth 10,660$ on 11 June 2015.

The largest trade Robert's ever made was exercising 10,000 units of Progenics Pharmaceuticals stock on 13 November 2014 worth over 53,300$. On average, Robert trades about 2,981 units every 40 days since 2003. As of 11 June 2015 Robert still owns at least 37,050 units of Progenics Pharmaceuticals stock.

You can see the complete history of Robert Israel stock trades at the bottom of the page.

Insiders trading at Progenics Pharmaceuticals

Over the last 22 years, insiders at Progenics Pharmaceuticals have traded over 11,559,939$ worth of Progenics Pharmaceuticals stock and bought 2,672,016 units worth 11,900,148$ . The most active insiders traders include Healthcare Master Fund Ltd ...、Michael D Kishbauch、Bradley L Campbell. On average, Progenics Pharmaceuticals executives and independent directors trade stock every 16 days with the average trade being worth of 60,241$. The most recent stock trade was executed by Capital, L.P.Altiva Managem... on 9 September 2019, trading 72,023 units of PGNX stock currently worth 359,395$.

What does Progenics Pharmaceuticals do?

Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. Maddon in 1986 and is headquartered in New York, NY.

Complete history of Robert Israel stock trades at Progenics Pharmaceuticals

Progenics Pharmaceuticals executives and stock owners

Progenics Pharmaceuticals executives and other stock owners filed with the SEC include:

• Partners, Llc Melkonian Cap...,
  
• Nicole Williams,
  Director
• Healthcare Master Fund Ltd ...,
  
• Healthcare Master Fund Ltd ...,
  
• Sheldon Hirt,
  Executive VP & General Counsel
• Michael D Kishbauch,
  Director
• David A Scheinberg,
  Director
• Karen Jean Ferrante,
  Director
• Peter J Crowley,
  Director
• Bradley L Campbell,
  Director
• Jeffery Summer,
  SVP, Digital Technology
• Patrick Fabbio,
  CFO
• Mark Robert Baker,
  CEO
• Charles A Baker,
  Director
• Kurt W Briner,
  Director
• Stephen P Goff,
  Director
• Mark F Dalton,
  Director
• Thomas A Boyd,
  SR. VP, Product Development
• Paul F Jacobson,
  Director
• Robert A Mckinney,
  VP of Finance and Admin
• Alton B Kremer,
  VP, Clinical Research
• Robert J Israel,
  Senior VP Medical Affairs
• Philip K Yachmetz,
  VP, Gen Counsel and Secretary
• Ronald J Prentki,
  President
• William C Olson,
  Senior VP, Research and Develo
• Paul J Maddon,
  Director
• Angelo William Jr Lovallo,
  Vice President Finance
• Hagop Youssoufian,
  Executive Vice President R&D
• Capital, L.P.Altiva Managem...,
  
• Heinz Christoph Maeusli,
  Director
• Gerard Ber,
  Director
• Ann L. Mac Dougall,
  Director
• Eric J Ende,
  Director
• Vivien Wong,
  EVP, Development
• David W. Mims,
  Interim CEO and Interim CFO
• Bryce Tenbarge,
  SVP, Commercial
• Benedict Osorio,
  COO
• Asha Das,
  Chief Medical Officer